ClinicalTrials.gg
TerminatedNCT00385593Updated Dec 16, 2010Results posted

Symbicort Single Inhaler Therapy vs Conventional Best Practice for the Treatment of Persistent Asthma in Adults

A Phase 3 interventional study of Symbicort (budesonide/formoterol) Turbuhaler and Conventional treatment in Asthma, Bronchial, sponsored by AstraZeneca. Terminated at 52 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-12-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
654
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 359 studies in Asthma by AstraZeneca — 19 open to participants now, 28 under way, 8 of them phase 3. Asthma · AstraZeneca.

Enrollment
54th of 248
654 · median 175
Started
2006
with 15 others
Phase 3
121 of 359
6 open now
Registered
48th of 359
by date

Among the 359 studies in Asthma by AstraZeneca, this one is the 54th largest by enrollment of the 248 interventional ones that give a count, is one of 16 that started in 2006, is one of 121 in phase 3, and was the 48th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

19 of the 359 studies in Asthma by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 359 studies in Asthma by AstraZeneca, or all of them as a file.
02

Study summary

This study is intended to extend the knowledge of Symbicort Single Inhaler Therapy into a more general setting in order to assess the real-life impact of introducing this new treatment concept. The study will compare the Symbicort Single Inhaler Therapy concept with a conventional stepwise treatment regimen according to the investigator's judgement in patients who present with symptoms on inhaled glucocorticosteroids (GCS) treatment or who require and are already on treatment with a combination of inhaled and long-acting B2 agonists (LABA).

03

Conditions studied

  • Asthma, Bronchial

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Minimum of 3 months history of asthma, diagnosed according to the American Thoracic Society (ATS) definition (9).
  • Prescribed inhaled GCS at a dose of 400μg/day of budesonide (or equivalents)and within the approved label for the relevant drug during the last 3 months prior to Visit 1.
  • Either daily maintenance treatment with both inhaled GCS and LABA or daily treatment with inhaled GCS alone (i.e. without LABA)
  • A history of suboptimal asthma control the month prior to enrolment as judged by the investigator
  • Use of ≥3 inhalations of as needed medication for symptom relief during the last 7 days before enrolment

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with Symbicort Single Inhaler;
  • Use of any b-blocking agent, including eye-drops and oral GCS as maintenance treatment.
  • Known or suspected to study therapy or .
  • A history of smoking ≥ 10 pack years.
  • Asthma exacerbation requiring change in asthma treatment during the last 14 days prior to or at Visit 1.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
654 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Time to First Severe Asthma Exacerbation

    Severe asthma exacerbation is defined as deterioration in asthma leading to at least one of Hospitalization/Emergency room (or equivalent) treatment due to asthma or Oral Glucocorticosteroids (GCS) treatment for at least 3 days.

    Time frame: Baseline up to 6 months

Secondary outcomes

  1. Total Number of Severe Exacerbations

    Severe asthma exacerbation is defined as deterioration in asthma leading to at least one of Hospitalization/Emergency room (or equivalent) treatment due to asthma or Oral (GCS) treatment for at least 3 days.

    Time frame: Baseline up to 6 months

  2. Mean Use of as Needed Medication

    Mean use of as needed medication during the treatment period

    Time frame: Baseline up to 6 months

  3. Use of Inhaled Steroids

    Mean micrograms/day of inhaled steroids (beclomethasone dipropionate equivalents)

    Time frame: Baseline up to 6 months

  4. Change in the Asthma Control Questionnaire(ACQ) Score

    The ACQ is a 7-point scale with scores ranging from 0 (very well controlled) to 6 (very badly controlled)

    Time frame: Daily 14 days prior to each of visit 2-4

  5. Peak Expiratory Flow (PEF)

    Peak expiratory flow (PEF)

    Time frame: 6 months (end of the study)

07

Results

Posted Nov 17, 2009
Limitations and caveats
The study was prematurely stopped, because it was not possible to recruit the sample size required in the period of time established.

Participant flow

654

Participant flow — Overall Study
MilestoneSMARTConv. Best Practice
Started328326
Completed270289
Not completed5837
Withdrew: Adverse event32
Withdrew: Withdrawal by subject177
Withdrew: Lost to follow-up128
Withdrew: Protocol violation74
Withdrew: Several reasons1715
Withdrew: Incorrect inclusion20
Withdrew: Incorrect randomization01

Outcome measures

PrimaryTime to First Severe Asthma Exacerbation

Severe asthma exacerbation is defined as deterioration in asthma leading to at least one of Hospitalization/Emergency room (or equivalent) treatment due to asthma or Oral Glucocorticosteroids (GCS) treatment for at least 3 days.

Time frame:
Baseline up to 6 months
Reported as:
Mean · Days
Time to First Severe Asthma Exacerbation
DaysSMARTConv. Best Practice
Time to First Severe Asthma Exacerbation174.39 ± 1.76178.97 ± 1.86
SecondaryTotal Number of Severe Exacerbations

Severe asthma exacerbation is defined as deterioration in asthma leading to at least one of Hospitalization/Emergency room (or equivalent) treatment due to asthma or Oral (GCS) treatment for at least 3 days.

Time frame:
Baseline up to 6 months
Reported as:
Number · Exacerbations
Total Number of Severe Exacerbations
ExacerbationsSMARTConv. Best Practice
Total Number of Severe Exacerbations2434
SecondaryMean Use of as Needed Medication

Mean use of as needed medication during the treatment period

Time frame:
Baseline up to 6 months
Reported as:
Mean · Inhalations
Mean Use of as Needed Medication
InhalationsSMARTConv. Best Practice
Mean Use of as Needed Medication1.03 ± 01.02 ± 0
SecondaryUse of Inhaled Steroids

Mean micrograms/day of inhaled steroids (beclomethasone dipropionate equivalents)

Time frame:
Baseline up to 6 months
Reported as:
Mean · micrograms
Use of Inhaled Steroids
microgramsSMARTConv. Best Practice
Use of Inhaled Steroids799 ± 2501184 ± 200
SecondaryChange in the Asthma Control Questionnaire(ACQ) Score

The ACQ is a 7-point scale with scores ranging from 0 (very well controlled) to 6 (very badly controlled)

Time frame:
Daily 14 days prior to each of visit 2-4
Reported as:
Mean · Scores on a scale
Change in the Asthma Control Questionnaire(ACQ) Score
Scores on a scaleSMARTConv. Best Practice
Change in the Asthma Control Questionnaire(ACQ) Score0.99 ± 0.01.08 ± 0.0
SecondaryPeak Expiratory Flow (PEF)

Peak expiratory flow (PEF)

Time frame:
6 months (end of the study)
Reported as:
Mean · L/min
Peak Expiratory Flow (PEF)
L/minSMARTConv. Best Practice
Peak Expiratory Flow (PEF)405.9 (110 to 900)400.6 (140 to 900)

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SMART—10/326 (3.1%)0/326 (0%)
Conv. Best Practice—5/326 (1.5%)0/326 (0%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventSMARTConv. Best Practice
GastroenteritisGastrointestinal disorders1/3260/326
Uterine LeiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3260/326
EpicondylitisMusculoskeletal and connective tissue disorders1/3260/326
Gene MutationCongenital, familial and genetic disorders1/3260/326
Medullary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/3260/326
Irritable Bowel SyndromeGastrointestinal disorders1/3260/326
PneumoniaInfections and infestations1/3261/326
DiarrhoeaGastrointestinal disorders1/3260/326
Respiratory Tract InfectionInfections and infestations1/3260/326
CataractEye disorders1/3260/326

Baseline characteristics

Age Continuous
Age Continuous(Years)SMARTConv. Best PracticeTotal
Mean43.7 ± 16.444.3 ± 16.544.0 ± 16.5
Sex: Female, Male
Sex: Female, Male(Participants)SMARTConv. Best PracticeTotal
Female218202420
Male110124234
08

Study locations

52 sites
  • Research Site
    A Coruna, Spain
  • Research Site
    Alagon, Spain
  • Research Site
    Alicante, Spain
  • Research Site
    Almoradi, Spain
  • Research Site
    Barcelona, Spain
  • Research Site
    Burgos, Spain
  • Research Site
    Cadiz, Spain
  • Research Site
    Caravaca, Spain
  • Research Site
    Cartagena, Spain
  • Research Site
    Cordoba, Spain
  • Research Site
    Coslada, Spain
  • Research Site
    Dos Hermanas, Spain
  • Research Site
    Elche, Spain
  • Research Site
    Fuencarral, Spain
  • Research Site
    Fuenlabrada, Spain
  • Research Site
    Galdacano, Spain
  • Research Site
    Gallur, Spain
  • Research Site
    Gandia, Spain
  • Research Site
    Getafe, Spain
  • Research Site
    Gijon, Spain
  • Research Site
    Granada, Spain
  • Research Site
    Huelva, Spain
  • Research Site
    Huesca, Spain
  • Research Site
    Idiazabal, Spain
  • Research Site
    Jaen, Spain
  • Research Site
    Lugo, Spain
  • Research Site
    Madrid, Spain
  • Research Site
    Malaga, Spain
  • Research Site
    Mataro, Spain
  • Research Site
    Oviedo, Spain
  • Research Site
    Pamplona, Spain
  • Research Site
    Pinto, Spain
  • Research Site
    Pozuelo de Alarcon, Spain
  • Research Site
    Sagunto, Spain
  • Research Site
    Salamanca, Spain
  • Research Site
    San Juan, Spain
  • Research Site
    San Sebastian, Spain
  • Research Site
    Santander, Spain
  • Research Site
    Santiago de Compostela, Spain
  • Research Site
    Santiago, Spain
  • Research Site
    Sevilla, Spain
  • Research Site
    Terrassa, Spain
  • Research Site
    Valdemoro, Spain
  • Research Site
    Valencia, Spain
  • Research Site
    Valladolid, Spain
  • Research Site
    Vigo, Spain
  • Research Site
    Viladecans, Spain
  • Research Site
    Vilanova, Spain
  • Research Site
    Villabona, Spain
  • Research Site
    Villanueva de la Canada, Spain
  • Research Site
    Vitoria, Spain
  • Research Site
    Zaragoza, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2006
First posted
Oct 9, 2006
Start
Sep 2006
CompletionActual
Oct 2008
Results first posted
Nov 17, 2009
Last update
Dec 16, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00385593
Lead sponsor
AstraZeneca
First posted
Oct 9, 2006
Start date
Sep 2006
Completion
Oct 2008
Results posted
Nov 17, 2009
Last update
Dec 16, 2010

Study contacts

Carlos Barcina, MD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide/Formoterol Fumarate Dihydrate Inhalation Aerosol

Start the discussion